A
Andrey Rubanov
Researcher at Discovery Institute
Publications - 5
Citations - 683
Andrey Rubanov is an academic researcher from Discovery Institute. The author has contributed to research in topics: Drug repositioning & Viral replication. The author has an hindex of 2, co-authored 4 publications receiving 417 citations.
Papers
More filters
Journal ArticleDOI
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
Laura Riva,Shuofeng Yuan,Xin Yin,Laura Martin-Sancho,Naoko Matsunaga,Lars Pache,Sebastian Burgstaller-Muehlbacher,Paul D. De Jesus,Peter Teriete,Mitchell V. Hull,Max W. Chang,Jasper Fuk-Woo Chan,Jianli Cao,Vincent Kwok-Man Poon,Kristina M. Herbert,Kuoyuan Cheng,Kuoyuan Cheng,Tu Trinh H. Nguyen,Andrey Rubanov,Yuan Pu,Courtney Nguyen,Angela Choi,Raveen Rathnasinghe,Michael Schotsaert,Lisa Miorin,Marion Dejosez,Thomas P. Zwaka,Ko Yung Sit,Luis Martinez-Sobrido,Wen-Chun Liu,Kris M. White,Mackenzie E. Chapman,Emma K. Lendy,Richard Glynne,Randy A. Albrecht,Eytan Ruppin,Andrew D. Mesecar,Jeffrey R Johnson,Christopher Benner,Ren Sun,Peter G. Schultz,Andrew I. Su,Adolfo García-Sastre,Arnab K. Chatterjee,Kwok-Yung Yuen,Sumit K. Chanda +45 more
TL;DR: A screen of the ReFRAME library of approximately 12,000 known drugs for antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified several candidate compounds with suitable activities and pharmacological profiles, which could potentially expedite the deployment of therapies for coronav virus disease 2019 (COVID-19).
Posted ContentDOI
A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals
Laura Riva,Shuofeng Yuan,Xin Yin,Laura Martin-Sancho,Naoko Matsunaga,Sebastian Burgstaller,Lars Pache,Paul D. De Jesus,Mitchell V. Hull,Max W. Chang,Jasper Fuk-Woo Chan,Jianli Cao,Vincent Kwok-Man Poon,Kristina M. Herbert,Tu-Trinh Nguyen,Yuan Pu,Courtney Nguyen,Andrey Rubanov,Luis Martinez-Sobrido,Wen-Chun Lui,Lisa Miorin,Kris M. White,Jeffrey R Johnson,Christopher Benner,Ren Sun,Peter G. Schultz,Andrew I. Su,Adolfo García-Sastre,Arnab K. Chatterjee,Kwok-Yung Yuen,Sumit K. Chanda +30 more
TL;DR: To identify therapeutics that can be repurposed as SARS-CoV-2 antivirals, a library of known drugs encompassing approximately 12,000 clinical-stage or FDA-approved small molecules is profiled, reporting the identification of 30 known drugs that inhibit viral replication.
Journal ArticleDOI
The Compound SBI-0090799 Inhibits Zika Virus Infection by Blocking De Novo Formation of the Membranous Replication Compartment.
Laura Riva,Sarah Goellner,Sarah Goellner,Scott B. Biering,Chun-Teng Huang,Andrey Rubanov,Uta Haselmann,Colin M. Warnes,Paul D. De Jesus,Laura Martin-Sancho,Alexey V. Terskikh,Eva Harris,Anthony B. Pinkerton,Ralf Bartenschlager,Ralf Bartenschlager,Sumit K. Chanda +15 more
TL;DR: In this paper, the (2E)-N-benzyl-3-(4-butoxyphenyl)prop-2-enamide (SBI-0090799) was found to inhibit replication of multiple ZIKV strains and in different cell systems.
Journal ArticleDOI
Engagement with daily testing instead of self-isolating in contacts of confirmed cases of SARS-CoV-2
Journal ArticleDOI
Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies
TL;DR: In this article , the authors summarized the various ways in which different DNA regions become more or less open, impacting patient response to anti-cancer therapies and discussed how aberrant chromatin, transcriptional, and epigenetic regulation contribute to therapy resistance.